Alnylam Pharmaceuticals, Inc.ALNY

Alnylam Pharmaceuticals is not a ticker; it’s a company with $3.71 billion in 2025 product revenue, $313.7 million in net income, and $1.66 billion in cash-numbers that look impressive until you realise $1.32 billion of that top line was burned on R&D, and the company still carries $4.18 billion in liabilities against $789.2 million in shareholders’ equity. The income statement is less a story of blockbusters and more a reminder that turning Nobel science into net income is a marathon, not a sprint, especially when your gross margin is getting squeezed by rising royalty rates and higher COGS. The company’s 2025 diluted EPS of $2.33 sits atop 134.7 million shares, which is the kind of base you don’t dilute lightly-yet insider filings in late May and early June suggest someone’s keen to keep the filing trail fresh.

What Alnylam actually does is sell four FDA-approved RNA interference therapies: AMVUTTRA (vutrisiran) for ATTR-CM, ONPATTRO (patisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1. The company’s patient services arm, Alnylam Assist®, offers the kind of white-glove support that turns a rare-disease prescription into a concierge experience-complete with dedicated hotlines, financial assistance, and even a glossy image of a smiling clinician holding a vial on the company’s website. But the website’s production-line photo, while photogenic, can’t hide the fact that AMVUTTRA’s commercial success is already pushing COGS to 20% of net product revenues in Q1 2026, up from 15% a year earlier, because the more vials you sell, the higher the blended royalty rate climbs. The company warns investors that COGS as a percentage of revenue will keep rising through 2026, which is corporate-speak for ‘margin pressure is baked in as AMVUTTRA scales.’

The balance sheet tells the clearer story. Cash and equivalents stood at $1.66 billion at year-end 2025, up from $1.2 billion a year earlier, but that increase was offset by a $58.7 million capex bill and a $8.5 million drawdown in inventory during 2025. Operating cash flow was a healthy $524.1 million, but net income was only $313.7 million, which means the company is generating cash faster than it’s converting it into bottom-line profit-a dynamic that’s fine until the royalty math tightens or the pipeline stumbles. The company’s R&D expense for 2025 was $1.32 billion, which is the cost of doing business in RNAi, but it also means that every dollar of net income is the net of a very large gross. Diluted shares outstanding averaged 134.7 million for 2025, and the company’s Form 4 and 8-K filings in late May and early June suggest insiders are keeping their filing trail up to date, which is the kind of visibility you get when the optics matter more than the dilution.

For context, Alnylam’s product revenues are heavily concentrated in its transthyretin amyloidosis franchise, particularly AMVUTTRA, which received FDA approval in March 2025 for ATTR-CM and has been the primary driver of the company’s 2025 and Q1 2026 revenue base. The company’s patient services portal and product pages are the public face of its commercial effort, but the filings are where the margin reality lives. The company’s Capella RNAi innovation hub is the science showcase, but the balance sheet is where the cost of that science lands. If you’re looking for a chart route, the SEC filings and XBRL company facts provide the raw data rails, while the company’s own product and patient services pages provide the human scene-though neither tells you how much cash is left once the royalty cheque clears.

What’s missing from the public rail is granular segment-level guidance beyond the broad revenue split and the warning that COGS as a percentage of revenue will rise in 2026. The company’s 10-K and 10-Q filings provide the revenue, net income, cash, and COGS figures, but they don’t break out the exact royalty rates or the per-vial manufacturing cost that would let investors model the margin squeeze. The company’s patient services and product pages are marketing-grade, not operational-grade, so they tell you what the company wants patients and prescribers to feel, not what investors can bank on. Until the company files a deeper segment breakout or a pipeline update tied to specific milestones, the file remains a tale of top-line growth and margin pressure rather than a story you can model from the footnotes.

The company’s 2026 Q1 results reiterate that AMVUTTRA is the revenue engine, but the filings also make clear that the margin pain is real: COGS as a percentage of net product revenues rose to 20% in Q1 2026 from 15% in Q1 2025, driven by higher AMVUTTRA sales and a rising blended royalty rate. The company expects the pressure to continue through 2026, which is the filing equivalent of saying ‘don’t model gross margins at 2025 levels.’ Meanwhile, the company’s inventory drawdown of $8.5 million in 2025 suggests supply-chain discipline, but it also hints at the risk that demand could outstrip supply if AMVUTTRA continues to scale. The company’s R&D burn of $1.32 billion in 2025 is the price of staying ahead in RNAi, but it also means that every blockbuster is funded by a very large cheque from the balance sheet.